Pharmaids Pharmaceuticals Ltd
16 Nov 2026 12:00 AM
Pharmaids Pharmaceuticals Ltd consolidated sales up 5.34% on year in Q2FY2027,
Pharmaids Pharmaceuticals Ltd`s net loss stood at Rs 1.81 crore in Q2FY2027 compared to a net loss of Rs 2.56 crore in Q2FY26. The revenue from operations improved marginally 5.34% to Rs 4.34 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.76 lakh crore, gaining 6.98%. It has slipped by 0.66% over last one week and gained upto 6.26% in last one month while the market capitalization of Pharmaids Pharmaceuticals Ltd has eased by 5% and 13.61% in the same period respectively.
Profit before tax (PBT) of Pharmaids Pharmaceuticals Ltd stood at Rs 2.37 crore in Q2 FY27, tumbling by 35.77% year-on-year, and crashing by 198.34% quarter-on-quarter. EBITDA came in at Rs 1 crore, nosediving by 75.14% YoY and rallying 69.62% sequentially.
Total expenses increased by 14.21% to Rs 6.11 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 1.73 crore, soaring by 74.75% YoY, while employee benefits expense was at Rs 2.5 crore, inching up 1.21% YoY.
For FY26, revenue from operations soared by 43.34% to Rs 27.88 crore, while net profit dropped 14.36% to Rs 11.57 crore, compared to previous FY. EBITDA saw a sharp decline of 1427% to Rs 13.82 crore, and PBT softened 5.67% to Rs 16.3 crore compared to previous FY.
The company`s consolidated net cash flow from operating activities stood at Rs 4.06 crore in FY26, as against Rs 15.11 crore in FY25.
Pharmaids Pharmaceuticals Ltd tumbled by 37.79% in last one year, underperforming the benchmark BSE Sensex which has softened by 3.42% during the same period.
Pharmaids Pharmaceuticals Ltd
12 Nov 2026 12:00 AM
Pharmaids Pharmaceuticals Ltd consolidated sales up 5.34% on year in Q2FY2027,
Pharmaids Pharmaceuticals Ltd share price slipped 2.77% to Rs 29.17 after the company`s net profit plunged by 196.79% to Rs 1.81 crore, while revenue from operations improved marginally 5.34% to Rs 4.34 crore in Q2FY27 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, rising 5.82%. It has marginally improved by 3.49% over last one week and moved up slightly by 6.26% in last one month while the market capitalization of Pharmaids Pharmaceuticals Ltd has improved by 0.28% and 12.77% in the same period respectively.
Profit before tax (PBT) of Pharmaids Pharmaceuticals Ltd stood at Rs 2.37 crore in Q2 FY27, plunging by 35.77% year-on-year, and nosediving by 198.34% quarter-on-quarter. EBITDA came in at Rs 1 crore, tanking 75.14% YoY and expanding by 69.62% sequentially.
Total expenses advancing by 14.21% to Rs 6.11 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 1.73 crore, jumping 74.75% YoY, while employee benefits expense was at Rs 2.5 crore, ticking higher by 1.21% YoY.
For FY26, revenue from operations witnessed a strong growth of 43.34% to Rs 27.88 crore, while net profit contracted by 14.36% to Rs 11.57 crore, compared to previous FY. EBITDA tumbled by 1427% to Rs 13.82 crore, and PBT softened 5.67% to Rs 16.3 crore compared to previous FY.
The company`s consolidated net cash flow from operating activities stood at Rs 4.06 crore in FY26, as against Rs 15.11 crore in FY25.
Pharmaids Pharmaceuticals Ltd nosedived by 40.45% in last one year, underperforming the benchmark BSE Sensex which has eased by 2.37% during the same period.
Pharmaids Pharmaceuticals Ltd
05 Nov 2026 12:00 AM
Pharmaids Pharmaceuticals to review financial results at board meeting on November 11, 2026,
Pharmaids Pharmaceuticals Limited will hold a board meeting on Wednesday, November 11, 2026, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing with the BSE Limited. The company’s trading window for securities will be closed from October 1, 2026, and will reopen 48 hours after the financial results are declared.
Pharmaids Pharmaceuticals Ltd
13 Oct 2026 12:00 AM
Pharmaids Pharmaceuticals Limited confirms regulatory compliance with SEBI for the September 30, 2026 period,
Pharmaids Pharmaceuticals Limited informed the BSE that it has received a certificate from Venture Capital and Corporate Investments Private Limited, acting as its registrar and share transfer agent, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter and half year ended September 30, 2026.
Pharmaids Pharmaceuticals Ltd
25 Sep 2026 12:00 AM
Pharmaids Pharmaceuticals restricts trading for insiders during financial results reporting period,
Pharmaids Pharmaceuticals Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the declaration of the company’s unaudited financial results for the quarter and half year ended September 30, 2026, in compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.
Subscribe for our
newsletter
newsletter
HSL Mobile App